New hope for advanced cancer: first human trial of APR-1051 begins
Disease control
Recruiting now
This early-stage study tests a new oral drug called APR-1051 in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose, while also looking for signs that it might shrink tumors. Pa…
Phase: PHASE1 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:48 UTC